ホーム › 多発性骨髄腫 › オハイオ › Columbus
Columbus、OHにおける多発性骨髄腫の臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
被験者募集中第3相
- Study Site 104, Columbus
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
被験者募集中第1/2相
- The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
被験者募集中第2相
- Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology, Columbus
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
被験者募集中第3相
- Ohio State University, Columbus
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- The Ohio State University- James Cancer Hospital, Columbus
- OhioHealth, Columbus
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Ohio State University Comprehensive Cancer Center, Columbus
Collection of Tissue Samples for Cancer Research
被験者募集中観察研究
- Ohio State University, Columbus
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- 他7件
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
被験者募集中第1/2相
- Ohio State University, Columbus
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, Columbus
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
被験者募集中第1相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
被験者募集中第1/2相
- The Ohio State University /ID# 271336, Columbus
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
被験者募集中第1相
- The Ohio State University James Cancer Hospital, Columbus
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Ohio State Medical Center, James Cancer Center, Columbus
- Ohio Health Research Institute, Columbus
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
被験者募集中第2相
- The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
被験者募集中第2相
- The Ohio State University Comprehensive Cancer Center, Columbus
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
被験者募集中
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- The Ohio State University, Columbus
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
被験者募集中第3相
- GSK Investigational Site, Columbus
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Ohio State University James Cancer Hospital, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
被験者募集中観察研究
- Ohio State University Medical Center, Columbus
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
- Seattle, WA22件の研究
Columbusにおける他の研究
- 非小細胞肺癌56件の研究
- 乳がん39件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 大腸癌24件の研究
- 前立腺がん24件の研究
- 悪性黒色腫21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。